Weik Investment Services Inc. continued to hold its stake in Allergan PLC. (NYSE:AGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 855 shares of the company’s stock at the close of the 2nd quarter. Weik Investment Services Inc.’s holdings in Allergan PLC. were worth $208,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in the business. Hudock Capital Group LLC increased its position in shares of Allergan PLC. by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after purchasing an additional 2 shares during the last quarter. GWM Advisors LLC boosted its holdings in shares of Allergan PLC. by 0.4% in the 1st quarter. GWM Advisors LLC now owns 1,260 shares of the company’s stock valued at $300,000 after buying an additional 5 shares in the last quarter. Burns J W & Co. Inc. NY boosted its holdings in shares of Allergan PLC. by 0.7% in the 2nd quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock valued at $220,000 after buying an additional 6 shares in the last quarter. Pacific Center for Financial Services boosted its holdings in shares of Allergan PLC. by 1.3% in the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after buying an additional 7 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of Allergan PLC. by 0.5% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock valued at $405,000 after buying an additional 9 shares in the last quarter. 82.04% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Weik Investment Services Inc. Continues to Hold Holdings in Allergan PLC. (AGN)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/10/12/weik-investment-services-inc-continues-to-hold-holdings-in-allergan-plc-agn.html.
Several research analysts have recently issued reports on the stock. Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a report on Monday, June 26th. Wells Fargo & Company restated an “outperform” rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a report on Wednesday, August 9th. Cowen and Company restated a “buy” rating on shares of Allergan PLC. in a report on Thursday. UBS AG restated an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a report on Wednesday, August 9th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $273.00 target price (up previously from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $271.64.
Shares of Allergan PLC. (AGN) opened at 206.61 on Thursday. The stock’s 50 day moving average is $216.96 and its 200-day moving average is $232.50. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The stock has a market capitalization of $69.07 billion, a P/E ratio of 6.29 and a beta of 1.15.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.35 EPS. On average, equities research analysts expect that Allergan PLC. will post $16.21 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.36%. Allergan PLC.’s dividend payout ratio is 9.95%.
Allergan PLC. declared that its Board of Directors has authorized a share repurchase plan on Monday, September 25th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
Allergan PLC. Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.